I am a researcher in pharmaceutics working at the intersection of advanced drug delivery, computational pharmacology, and translational pharmaceutical sciences. My research focuses on the design and development of lipid–drug conjugates, nanocarrier systems, and repurposed therapeutics to enhance drug bioavailability, improve pharmacokinetic behavior, and overcome biological barriers such as the blood–brain barrier. A major objective of my work is to develop innovative delivery strategies that enable more effective treatment of neurological disorders, particularly migraine. I am pursuing my doctoral research at The Maharaja Sayajirao University of Baroda, where my work centers on novel drug delivery systems for anti-migraine therapeutics. My research integrates experimental pharmaceutics with computational approaches, including molecular docking, in-silico pharmacokinetic prediction, and model-informed drug development strategies. Through these approaches, I investigate the potential of lipid conjugation and nanocarrier technologies to improve therapeutic performance, stability, and targeted drug delivery. My doctoral research is supported by the prestigious Prime Minister’s Doctoral Research Fellowship (PMDRF), a nationally competitive program established by the Government of India to promote high-impact doctoral research through strong academia–industry collaboration. As part of this fellowship, my research is conducted in collaboration with DWD Pharmaceuticals Ltd.. This partnership provides a translational research environment that bridges academic innovation with industrial drug development, allowing exploration of formulation strategies, predictive modeling, and scalable pharmaceutical technologies with real-world applications. My work combines in-silico drug design, molecular docking, pharmacokinetic and pharmacodynamic modeling, and experimental formulation development. I have experience with computational tools and modeling platforms for predicting drug behavior, identifying potential targets, and guiding formulation design. In addition, my research involves extensive experimental characterization using analytical and formulation techniques such as HPLC, UV-visible spectroscopy, FTIR, DSC, particle size analysis, and zeta potential measurements. These combined experimental and computational strategies support a model-informed approach to drug development, enabling the integration of laboratory and predictive data to guide therapeutic innovation. My research outputs include peer-reviewed journal publications, book chapters on advanced drug delivery technologies, conference presentations, and pharmaceutical patent applications. My work has contributed to areas such as lipid-drug conjugates for CNS delivery, nanocarrier-based therapeutic systems, nanoemulsion formulations, and hybrid nanoparticle platforms for oncology and neurological applications. These contributions aim to expand the application of nanomedicine and formulation science in addressing complex therapeutic challenges. In addition to research, I have been actively involved in teaching and mentoring pharmacy students during my doctoral training. This includes supporting laboratory instruction, guiding students in pharmaceutics experiments, and contributing to academic learning in drug delivery and pharmaceutical technology. Teaching has strengthened my ability to communicate scientific concepts, mentor young researchers, and foster collaborative learning environments. My broader research interests include nanocarrier-based drug delivery, lipid-based formulation systems, drug repurposing strategies, computational pharmacology, quantitative systems pharmacology, pharmacokinetic modeling, and AI-assisted formulation design. I am particularly interested in approaches that integrate formulation science, computational modeling, and translational pharmacology to support model-informed drug development and predictive therapeutic design. Through interdisciplinary research that combines pharmaceutical formulation, computational modeling, and translational science, I aim to contribute to the development of predictive and scalable drug delivery solutions that accelerate the translation of pharmaceutical discoveries from laboratory research to clinical application and industrial development.